Nektar Therapeutics Non Peo Neo Avg Comp Actually Paid Amt
Nektar Therapeutics (NKTR) reported Non Peo Neo Avg Comp Actually Paid Amt of $1.92 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-24.
Financial Statements › Cash Flow › Other Cash Flow Items
ecd:NonPeoNeoAvgCompActuallyPaidAmt · last filed 2026-04-24
| Period end | Non Peo Neo Avg Comp Actually Paid Amt 12 month |
|---|---|
| 2025-12-31 | $1.92M DEF 14A · filed 2026-04-24 |
| 2024-12-31 | $1.43M DEF 14A · filed 2026-04-24 |
| 2023-12-31 | -$2.64K DEF 14A · filed 2026-04-24 |
| 2022-12-31 | -$3.43M DEF 14A · filed 2026-04-24 |
| 2021-12-31 | $3.29M DEF 14A · filed 2026-04-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |